KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Receivables - Net: 2011-2025

Historic Receivables - Net for Sarepta Therapeutics (SRPT) over the last 15 years, with Sep 2025 value amounting to $395.7 million.

  • Sarepta Therapeutics' Receivables - Net fell 8.93% to $395.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $395.7 million, marking a year-over-year decrease of 8.93%. This contributed to the annual value of $602.0 million for FY2024, which is 50.38% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Receivables - Net of $395.7 million as of Q3 2025, which was down 24.95% from $527.3 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Receivables - Net ranged from a high of $659.4 million in Q1 2025 and a low of $118.2 million during Q1 2021.
  • For the 3-year period, Sarepta Therapeutics' Receivables - Net averaged around $412.5 million, with its median value being $395.7 million (2025).
  • Per our database at Business Quant, Sarepta Therapeutics' Receivables - Net spiked by 86.52% in 2023 and then decreased by 8.93% in 2025.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Receivables - Net stood at $153.0 million in 2021, then surged by 40.28% to $214.6 million in 2022, then soared by 86.52% to $400.3 million in 2023, then skyrocketed by 50.38% to $602.0 million in 2024, then dropped by 8.93% to $395.7 million in 2025.
  • Its Receivables - Net was $395.7 million in Q3 2025, compared to $527.3 million in Q2 2025 and $659.4 million in Q1 2025.